JohnJosephRinehartMD

Oncology • Lexington, KY

Professor, Medicine University of Kentucky College of Medicine Lexington, Kentucky

Join to view full profile

Are you Dr. Rinehart?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 79 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
740 S Limestone
Lexington, KY 40536
Phone+1 859-323-5981

Fax+1 859-257-6002
Is this information wrong?

Summary

Dr. John Rinehart, MD is an oncologist in Lexington, Kentucky. He is currently licensed to practice medicine in Kentucky, Alabama, and Texas. He is affiliated with UK HealthCare Good Samaritan Hospital and is a Professor at Kentucky.

Education & Training

Ohio State University HospitalResidency, Internal Medicine, 1972 - 1974
University of ChicagoResidency, Internal Medicine, 1971 - 1972
Ohio State University HospitalInternship, Internal Medicine, 1970 - 1971
Ohio State University College of MedicineClass of 1970

Certifications & Licensure

KY State Medical License 2004 - 2025
OH State Medical License 1970 - 2018
AL State Medical License 1999 - 2004
TX State Medical License 1991 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer Start of enrollment: 2002 Feb 01
Completed
Phase 2
Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2005 Sep 01
Withdrawn
Phase 2
Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer Start of enrollment: 2005 Oct 01
Terminated
Phase 2
Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer Start of enrollment: 2005 Nov 01
Terminated
Phase 3
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer Start of enrollment: 2005 Aug 01
Completed
Phase 2
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

69 citations
Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Jonathan Feddock, Susanne M. Arnold, Brent J. Shelton, Partha Sinha, Gary R. Conrad, Li Chen, John Rinehart, Ronald C. McGarry> ;International Journal of Radiation Oncology, Biology, Physics. 2013 Apr 1
13 citations
Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer
John Rinehart, Susanne M. Arnold, Goetz H. Kloecker, Allen Lim, Muhammad Ali Zaydan, Thomas Baeker, Jewraj G. Maheshwari, Harry Carloss, Stacey Slone, Brent J. Shelton...> ;Cancer Chemotherapy and Pharmacology. 2013 Mar 9
9 citations
Risk for fatal pulmonary hemorrhage does not appear to be increased following dose escalation using stereotactic body radiotherapy (SBRT) in locally advanced non-small...
Jonathan Feddock, Ryan Cleary, Susanne M. Arnold, Brent J. Shelton, Partha Sinha, Gary R. Conrad, Li Chen, John Rinehart, Ronald C. McGarry> ;Journal of Radiosurgery and SBRT. 2013 Jan 1
Early PET/CT scans for assessing treatment responses of non-small cell lung cancer for SBRT boost: what to do with scans from multiple scanners.
Ronald C. McGarry, Jonathan Feddock, Partha Sinha, Gary R. Conrad, Brent J. Shelton, Li Chen, Susanne M. Arnold, John Rinehart> ;Journal of Radiosurgery and SBRT. 2013 Jan 1
9 citations
High Payload Dual Therapeutic‐Imaging Nanocarriers for Triggered Tumor Delivery
Jin-Ki Kim, Hong Yuan, Jingxin Nie, Yu Tsai Yang, Markos Leggas, Philip M. Potter, John Rinehart, Michael Jay, Xiuling Lu> ;Small. 2012 Sep 24
3 citations
Carboxylesterase-triggered hydrolysis of nanoparticle PEGylating agents.
Melissa D. Howard, Xiuling Lu, John Rinehart, Michael Jay, Thomas D. Dziubla> ;Langmuir. 2012 Aug 8
42 citations
Exploring Geographic Variation in Lung Cancer Incidence in Kentucky Using a Spatial Scan Statistic: Elevated Risk in the Appalachian Coal-Mining Region
W. Jay Christian, Bin Huang, John Rinehart, Claudia Hopenhayn> ;Public Health Reports. 2011 Nov 1
A phase I study evaluating the pharmacokinetics of components of S-1 in pts with varying degrees of renal function.
Saif MW, Lichinitser M, Gordon MS, Tan BR, Scheulen ME, Pandya NB, Sarantopoulos J, Rinehart JJ, Verschraegen CF, Lenz H, Zergebel C, Saito K> ;J. Clin. Oncol.. 2011-05-20
Utilization of neoadjuvant chemotherapy in stages II and III urothelial carcinoma of the bladder.
Huang B, Tucker T, Bylund JR, Rinehart JJ, Rowland RG, Strup SE, Crispen PL> ;J. Clin. Oncol.. 2011-03-01
14 citations
Physicochemical Characterization of Nanotemplate Engineered Solid Lipid Nanoparticles
Melissa D. Howard, Xiuling Lu, John Rinehart, Michael Jay, Thomas D. Dziubla> ;Langmuir. 2011 Mar 1
16 citations
Uniformity of Drug Payload and Its Effect on Stability of Solid Lipid Nanoparticles Containing an Ester Prodrug
Jin-Ki Kim, Melissa D. Howard, Thomas D. Dziubla, John Rinehart, Michael Jay, Xiuling Lu> ;ACS Nano. 2011 Jan 25
191 citations
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia LoRusso, Smitha S. Krishnamurthi, John J. Rinehart, Lisle Nabell, Lisa Malburg, Paul B. Chapman, Samuel E. DePrimo, Steven Bentivegna, Keith D. Wilner, Weiwei...> ;Clinical Cancer Research. 2010 Mar 15
20 citations
A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies
Susanne M. Arnold, John Rinehart, Eleftheria Tsakalozou, John R. Eckardt, Scott Z. Fields, Brent J. Shelton, Philip A. DeSimone, Bryan K. Kee, Jeffrey A. Moscow, Marko...> ;Clinical Cancer Research. 2010 Jan 15
Pharmacokinetics (PK) of the highly lipophilic and blood stable camptothecin AR-67 (7-t-butyldimethylsilyl-10- hydroxycamptothecin) in adult patients with solid malign...
Leggas M, Horn J, Tsakalozou E, Moscow JA, Fields SZ, Houchins JC, Eckardt JR, DeSimone P, Kee BK, Rinehart JJ, Arnold SM> ;J. Clin. Oncol.. 2009-05-20
Clinical and pharmacokinetic (PK) findings in a phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in patients with refractory solid tumors.
Arnold SM, Horn J, Eckardt JR, Rinehart JJ, DeSimone P, Fields SZ, Kee BK, Moscow JA, Houchins JC, Leggas M> ;J. Clin. Oncol.. 2009-05-20
27 citations
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy
Markos Leggas, Kuei-Ling Kuo, Francisco Robert, Gretchen A. Cloud, Mollie deShazo, Ruiwen Zhang, Mao Li, Hui Wang, Steve Davidson, John Rinehart> ;Cancer Chemotherapy and Pharmacology. 2009 Mar 1
20 citations
Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants II: Role of Plasma Esterases in Drug Release
Xiuling Lu, Melissa D. Howard, Dominique R. Talbert, John Rinehart, Philip M. Potter, Michael Jay, Markos Leggas> ;The AAPS Journal. 2009 Feb 19
25 citations
Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants: Optimization and In Vitro Characterization
Xiuling Lu, Melissa D. Howard, Marta Mazik, Joshua A. Eldridge, John Rinehart, Michael Jay, Markos Leggas> ;The AAPS Journal. 2008 Mar 4
59 citations
Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmac...
Hui Wang, Ying Wang, Elizabeth R. Rayburn, Donald L. Hill, John J. Rinehart, Ruiwen Zhang> ;International Journal of Oncology. 2007 Apr 1
Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer
Pierre L. Triozzi, Graeme B. Bolger, Jeffrey Neidhart, John J. Rinehart, Mansoor N. Saleh, Karen O. Allen, Sandra Sellers, Mary J. Waddell> ;The Prostate. 2005 Dec 1
Phase I trial of dexamethasone (Dex), carboplatin (C) and gemcitabine (G) in untreated non-small cell lung cancer (NSCLC).
Rinehart JJ, Davidson S, Deshazo M, Cloud G, Busby L, Robert F> ;J. Clin. Oncol.. 2005-06-01
5 citations
Neoadjuvant and concomitant chemotherapy and radiation therapy in patients with advanced head and neck carcinoma.
John J. Rinehart, Tibor Ruff, Alan Cheung, Lewis Hutchinson, Roger Tuggle, D. Randall Pinkston, Lisa Keville, Lucas Wong> ;Otolaryngology--Head and Neck Surgery. 2005 Jan 1
485 citations
Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer
John J. Rinehart, Alex A. Adjei, Patricia Lorusso, David Waterhouse, J. Randolph Hecht, Ronald B. Natale, Oday Hamid, Mary Varterasian, Peggy Asbury, Eric Kaldjian, St...> ;Journal of Clinical Oncology. 2004 Nov 15
Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer.
Rinehart JJ, Rothermel JD, Anderson J, Lorusso P> ;J. Clin. Oncol.. 2004-07-15
99 citations
Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts: In Vivo Activity, Pharmacokinetics...
Hui Wang, Mao Li, John J. Rinehart, Ruiwen Zhang> ;Clinical Cancer Research. 2004 Mar 1
Join now to see all

Grant Support

Dexamethasone/Carboplatin/Gemcitabine Untreated NsclcNational Center For Research Resources2004
Core--Clinical TrialsNational Cancer Institute2000–2002
Clinical Oncology Research Career Development ProgramNational Cancer Institute2000–2002
Trial Of L-377202 Once Every Three WeeksNational Center For Research Resources2000
Scott And White Community Clinical Oncology ProgramNational Cancer Institute1997
Southwest Oncology GroupNational Cancer Institute1993–1997
Chemotherapy And Biologics In A Murine Tumor ModelNational Cancer Institute1991
Phase IB Trial Of IL-2 Alone Or With Cytotoxic CellsDivision Of Cancer Treatment1988–1990

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

UK HealthCare Good Samaritan HospitalLexington, Kentucky